What Is a Pancreatic Cyst? Types, Symptoms, and Treatment

A pancreatic cyst is a fluid-filled sac that forms in or on the pancreas, the organ behind your stomach that produces digestive enzymes and insulin. Most are discovered by accident during imaging scans done for unrelated reasons, and most never cause any harm. But a small subset of pancreatic cysts are precancerous or already cancerous, which is why the diagnosis tends to set off a chain of follow-up tests, surveillance schedules, and sometimes difficult decisions about surgery. The challenge for you and your doctors is figuring out which kind you have.

How Common Are Pancreatic Cysts

Far more common than most people realize. An MRI-based study found incidental pancreatic cysts in about 13.5% of adults scanned for other reasons, with prevalence climbing steadily with age.¹ A separate prospective study using highly sensitive imaging reported an even higher weighted prevalence of roughly 49%, with an average of nearly four cysts per person among those who had any.² The gap between those figures reflects differences in imaging sensitivity and study design, but the takeaway is consistent: as imaging technology improves and more people get scanned, more cysts get found. Autopsy studies place the rate somewhere between a quarter and nearly half of all adults.³ In every dataset, older age means more cysts and bigger cysts.

This widespread detection has created a genuine clinical dilemma. The vast majority of these cysts will never progress to cancer or cause symptoms. But distinguishing the harmless ones from the dangerous ones remains difficult, and the stakes of getting it wrong run in both directions: miss a precancerous cyst, and a patient may develop pancreatic cancer, one of the deadliest malignancies. Over-treat a benign cyst, and a patient undergoes major surgery they never needed.

Pseudocysts Versus True Cysts

The first distinction doctors make is whether the cyst is a pseudocyst or a true cyst. A pseudocyst forms after the pancreas is injured, usually from a bout of pancreatitis or abdominal trauma. It fills with pancreatic fluid but lacks an inner lining of cells. That absence of a cellular lining is what makes it “pseudo.”⁴ True cysts, by contrast, do have a cellular lining, and their behavior depends entirely on what type of cells make up that lining.

Pseudocysts are not precancerous. Many resolve on their own. When they cause problems, it is usually because they grow large enough to press on surrounding structures, cause pain, or become infected. Treatment for a large or symptomatic pseudocyst typically involves drainage, either through an endoscope passed through the stomach or with a catheter placed through the skin. The more complex question, and where most of the medical uncertainty lives, concerns the true cystic neoplasms.

Serous Cystadenomas

Among true cysts, serous cystadenomas are the most common benign type seen on imaging.⁵ They are filled with thin, watery fluid and often have a distinctive honeycomb-like appearance on CT or MRI, sometimes with a visible central scar.⁶ If a radiologist can confidently identify a cyst as a serous cystadenoma based on these features, no further follow-up is generally needed because the risk of cancer is essentially zero.

The problem is that serous cystadenomas do not always look like the textbook description. They can appear as a single large cyst or take on irregular shapes that mimic mucinous cysts, the kind that do carry cancer risk. When the imaging is ambiguous, additional testing is needed to sort them out, which leads to the diagnostic tools discussed later in this article.

Mucinous Cysts and Their Cancer Risk

The cyst types that drive most of the clinical anxiety are the mucinous ones, which produce thick, mucus-like fluid and carry a real, if variable, risk of progressing to pancreatic cancer. The two major mucinous types are intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs).

Intraductal Papillary Mucinous Neoplasms

IPMNs are the most commonly encountered precancerous pancreatic cysts. They grow within the pancreatic duct system and are classified by which ducts they involve. Main-duct IPMNs grow in the central pancreatic duct and carry substantially higher cancer risk than branch-duct IPMNs, which arise in the smaller side branches.⁷ A meta-analysis examining specific features found that cyst size above 3 cm, the presence of a solid nodule growing from the cyst wall, and dilation of the main pancreatic duct were all strongly associated with malignancy.⁸ Some people also have “combined” IPMNs involving both the main duct and side branches.

Most branch-duct IPMNs, however, are small and slow-growing. Many people live with them for years or decades without any progression. The question of when to operate and when to watch is one of the most debated topics in pancreatic medicine.

Mucinous Cystic Neoplasms

MCNs are different from IPMNs in an interesting way: they occur almost exclusively in women. One large surgical series found that 98% of patients with MCNs confirmed by the presence of a distinctive tissue called ovarian-type stroma were female, and the vast majority were benign adenomas, with about 7% harboring invasive cancer.⁹ A more recent study confirmed this overwhelming female predominance and found that all MCNs contained this ovarian-like stroma, which stains positive for estrogen and progesterone receptors.¹⁰ MCNs tend to appear in the body or tail of the pancreas rather than the head, and they do not communicate with the pancreatic duct, which helps distinguish them from IPMNs.

Because MCNs do carry some cancer potential, the standard recommendation is surgical removal when the patient is a reasonable surgical candidate, especially if the cyst shows worrisome features like large size or internal nodules.

Solid Pseudopapillary Neoplasms and Other Rare Types

Solid pseudopapillary neoplasms (SPNs) are uncommon pancreatic tumors that can have cystic components and tend to occur in young women. On CT scans, they often appear as large, mixed solid-and-cystic masses in the body or tail of the pancreas, sometimes with hemorrhage inside.¹¹ SPNs are considered low-grade malignancies. They rarely spread, and surgical removal is usually curative. Distinguishing them from pancreatic neuroendocrine tumors can be tricky on imaging alone and sometimes requires specialized lab staining of tissue samples.¹²

Other rare cystic lesions include cystic neuroendocrine tumors and lymphoepithelial cysts. These are unusual enough that most general readers will never encounter them, but they are worth mentioning because they add to the diagnostic challenge: more possible cyst types means more room for misdiagnosis.

Symptoms, or the Usual Lack Thereof

Most pancreatic cysts cause no symptoms at all. They are typically discovered when you get a CT scan or MRI for something else entirely: back pain, a kidney stone, a car accident, or a routine check-up. This “incidental” discovery is the norm, not the exception.

When symptoms do occur, they tend to be vague and easily attributed to other things:

• Abdominal pain: a dull ache in the upper belly or back, sometimes worsened by eating.
• Nausea or vomiting: usually related to a large cyst pressing on the stomach or duodenum.
• Jaundice: yellowing of the skin and eyes, which happens when a cyst in the head of the pancreas blocks the bile duct. This is considered a high-risk sign.
• Pancreatitis: inflammation of the pancreas, which can be triggered by a cyst obstructing the pancreatic duct.
• Weight loss: unexplained weight loss alongside a pancreatic cyst is a red flag that warrants urgent evaluation.

Jaundice and unexplained weight loss are particularly concerning because they can signal that a cyst has progressed to advanced dysplasia or cancer. A systematic review found that obstructive jaundice was significantly associated with high-grade dysplasia or invasive cancer in IPMNs.¹³

How Pancreatic Cysts Are Diagnosed

The initial discovery usually happens on a CT or MRI scan. Both imaging methods are reasonably good at classifying cysts as mucinous versus non-mucinous, with accuracy in the range of 71% to 84%, though they are less reliable at pinpointing the exact cyst type.¹⁴ MRI with a special pancreatic-duct protocol is generally preferred for ongoing surveillance because it avoids radiation and offers good visualization of the duct system.

When imaging alone is not conclusive, the next step is often endoscopic ultrasound (EUS), in which a thin scope with an ultrasound probe is passed through the mouth into the stomach. The probe sits close to the pancreas and produces detailed images. During the same procedure, a needle can be passed through the scope to sample the cyst fluid. Analysis of that fluid provides several diagnostic clues. A carcinoembryonic antigen (CEA) level above 192 ng/mL is a widely used cutoff for distinguishing mucinous from non-mucinous cysts, with reasonable accuracy.¹⁵ High amylase levels in the fluid suggest a connection to the pancreatic duct, pointing toward a pseudocyst or IPMN. Newer molecular tests looking for specific gene mutations in the fluid can identify mucinous cysts with higher accuracy than CEA alone.¹⁵

Deciding Between Surveillance and Surgery

This is where the management of pancreatic cysts gets genuinely difficult. Several sets of international guidelines exist, and they do not always agree on which cysts to watch, which to operate on, and how often to scan.¹⁶ What they do share is a framework of “worrisome features” and “high-risk stigmata” that help stratify your risk.

High-risk stigmata are findings that strongly suggest cancer may already be present. These include obstructive jaundice caused by the cyst, a main pancreatic duct dilated to 10 mm or more, and suspicious or positive results on fluid analysis. A study evaluating updated international guidelines found that having multiple high-risk stigmata substantially increased the odds of finding advanced disease.¹³ When high-risk stigmata are present, surgery is generally recommended for patients who are fit enough to undergo it.

Worrisome features sit a level below that on the concern scale. These include things like a cyst growing faster than 2.5 mm per year, a mildly dilated pancreatic duct, or an abrupt change in duct size with shrinkage of the downstream pancreas. One study of branch-duct IPMNs found that having multiple worrisome features carried a dramatically higher rate of progressing to high-risk status compared with having none or just one.¹⁷ A cyst growth rate above 2.5 mm per year was itself a significant predictor.¹⁸

For cysts without any of these red flags, surveillance with periodic MRI is the standard approach. The intervals vary by guideline and by cyst size, but you can expect scans every six months to two years, potentially for many years. This can be reassuring (someone is watching), but it also generates its own burden.

Treatment Options

When surgery is indicated, the operation depends on where the cyst sits in the pancreas. A cyst in the head of the pancreas usually requires a Whipple procedure, which removes the head of the pancreas along with parts of the small intestine and bile duct. A cyst in the body or tail is typically addressed with a distal pancreatectomy, which removes the left portion of the pancreas and sometimes the spleen. Both are major operations with real recovery times and potential long-term consequences.

For patients who are not good surgical candidates, or for small cysts where surgery feels disproportionate, minimally invasive endoscopic treatments are gaining ground. EUS-guided ablation involves passing a needle into the cyst through an endoscope and injecting agents that destroy the cyst lining. Studies have examined ethanol injection, the chemotherapy drug paclitaxel, and combinations of both. A meta-analysis found an overall complete cyst resolution rate of about 53%, with the combination of ethanol followed by paclitaxel performing better than ethanol alone, at roughly 66% versus 47%.¹⁹ The adverse event rate was about 18%, though it was lower in the combination group. Newer techniques like radiofrequency ablation delivered through the endoscope have shown promise in small studies but are not yet standard practice.²⁰

Life After Pancreatic Surgery

Removing part of the pancreas is not without consequences, even when the operation goes smoothly and the cyst turns out to be benign. One long-term follow-up study of patients who had surgery for cystic neoplasms found that about 29% developed new-onset diabetes, typically within the first year after the operation.²¹ Half of patients showed signs of malnutrition, yet fewer than 8% were taking pancreatic enzyme supplements, suggesting the digestive consequences of losing pancreatic tissue were being under-treated. Another study of high-risk patients who underwent surgery found that 70% developed pancreatic exocrine insufficiency, meaning the remaining pancreas could not produce enough digestive enzymes.²²

These numbers matter because they feed directly into the overdiagnosis problem. Some patients end up having major surgery for cysts that would never have become cancer, and they carry the metabolic and nutritional consequences for life. Current guidelines acknowledge this tension explicitly.²³ The ideal would be better diagnostic tools that can reliably separate the dangerous cysts from the harmless ones before anyone reaches the operating room.

The Psychological Weight of Surveillance

Something that rarely gets discussed in medical overviews is the emotional toll of being told you have a pancreatic cyst and need regular scanning. Pancreatic cancer is one of the most feared diagnoses, and the word “pancreas” in any medical context tends to provoke anxiety. Research on individuals undergoing intensified pancreatic surveillance showed that cancer-related worry scores rose during the active surveillance period but returned to baseline after the surveillance period ended.²² General anxiety and depression scores, reassuringly, were not affected long-term. Still, years of scanning, waiting for results, and wondering whether this is the scan that finds something represent a real cost, even if it does not show up in a surgical complication rate.

Lifestyle Factors and Who Gets Pancreatic Cysts

Age is the strongest predictor: the older you are, the more likely you are to have a cyst and the larger it is likely to be. But several modifiable risk factors have been linked to cyst development. A study of individuals with diabetes found that current smokers had about a 1.4-fold higher risk of developing pancreatic cystic neoplasms than nonsmokers, and even mild alcohol consumption in people with diabetes was associated with elevated risk.²⁴ Metabolic syndrome, the cluster of high blood pressure, high blood sugar, abnormal cholesterol, and excess abdominal fat, has also been tied to a higher prevalence of IPMNs, especially in older adults. One study found that elderly patients with metabolic syndrome had about three times the odds of having an IPMN compared with those without it.²⁵

None of this means you can prevent a pancreatic cyst by living a certain way, but it does suggest that the same metabolic health habits that lower your risk of heart disease and many cancers may also slow the development of precancerous pancreatic changes.

Pancreatic Cysts in Children

Pancreatic cysts in children are rare and look quite different from the adult versions. The mix of cyst types in kids differs widely from what is seen in adults, with a broader range of non-neoplastic causes including congenital cysts and cysts related to conditions like cystic fibrosis.²⁶ The adult guidelines for surveillance and management do not apply to pediatric patients, and any pancreatic cyst found in a child should be evaluated at a center with pediatric surgical expertise.

Artificial Intelligence and the Future of Cyst Diagnosis

One of the most active areas of research is using AI and radiomics, the extraction of quantitative features from medical images, to improve cyst classification without invasive procedures. Machine learning models trained on CT and MRI data can pick up patterns invisible to the human eye, potentially distinguishing mucinous from non-mucinous cysts and identifying high-risk IPMNs with greater accuracy than current methods.²⁷ These tools remain largely in the research phase and have not yet been validated in large prospective trials, but they represent a realistic path toward reducing both missed cancers and unnecessary surgeries.²⁸ If they prove reliable, they could eventually change the surveillance experience entirely: fewer invasive needle aspirations, more confident scan-based decisions, and less time spent in the anxious limbo of “probably fine, but we need to keep watching.”